Submitted by dcc on Thu, 2017-02-16 13:44 Study Title: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected MelanomaCIRB: Adult CIRB - Late Phase EmphasisLead Group: SWOGStatus: ActiveReview Status: Available to Open
